Mishima Kazuo
Department of Psychophysiology, National Institute of Mental Health, National Center for Neurology and Psychiatry.
Nihon Rinsho. 2012 Jun;70(6):1069-78.
Ramelteon is a new class of sleep agent that selectively binds to the melatonin type 1 (MT1) and type 2 (MT2) receptors in the suprachiasmatic nucleus (SCN), instead of binding to GABA-A receptors such as with traditional hypnotics benzodiazepines. Ramelteon exhibits not only acute sleep-promoting effect but also circadian phase-shifting effect via MT1 and MT2 receptors respectively, and has been revealed to contribute to the treatment of acute and chronic insomnia in patients with circadian rhythm sleep disorders(sleep-wake rhythm disorders) or with inappropriate timing of sleep habits. Optimal administration plan for insomniac patients to induce these characteristic sleep-modulating effects by ramelteon was discussed.
雷美替胺是一种新型睡眠药物，它选择性地与视交叉上核（SCN）中的褪黑素1型（MT1）和2型（MT2）受体结合，而不像传统催眠药苯二氮䓬类那样与GABA - A受体结合。雷美替胺不仅具有促进睡眠的急性作用，还分别通过MT1和MT2受体发挥昼夜节律相移作用，并且已被证明有助于治疗昼夜节律睡眠障碍（睡眠 - 觉醒节律障碍）或睡眠习惯时间不当的急性和慢性失眠患者。本文讨论了失眠患者通过雷美替胺诱导这些特征性睡眠调节作用的最佳给药方案。
